Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China

Shuli Qu; Xuedan You; Tianyi Liu; Lijiao Wang; Zheng Yin; Yanjun Liu; Chong Ye; Ting Yang; Mao Huang; Hongchao Li; Liwen Fang; Jinping Zheng

doi:10.1038/s41533-021-00233-z

Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China

NPJ Prim Care Respir Med. 2021 May 20;31(1):28. doi: 10.1038/s41533-021-00233-z.

Authors

Shuli Qu¹, Xuedan You², Tianyi Liu², Lijiao Wang², Zheng Yin¹, Yanjun Liu¹, Chong Ye¹, Ting Yang³, Mao Huang⁴, Hongchao Li⁵, Liwen Fang⁶, Jinping Zheng⁷

Affiliations

¹ Real-World Insights, IQVIA, Beijing, China.
² Medical Affairs, AstraZeneca, Beijing, China.
³ National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine Chinese Academy of Medical Science; Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
⁴ Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
⁵ Department of Health Economics, School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
⁶ National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
⁷ National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. jpzhenggy@163.com.

Abstract

We built a decision-analytic model to compare the cost-effectiveness of using portable spirometer and questionnaire to screen chronic obstructive pulmonary diseases (COPD) with no screening (i.e. usual care) among chronic bronchitis patient in China. A lifetime horizon and a payer perspective were adopted. Cost data of health services including spirometry screening and treatment costs covered both maintenance and exacerbation. The result indicated that portable spirometer screening was cost-saving compared with questionnaire screening and no screening, with an incremental cost-effectiveness ratio (ICER) of -5026 and -1766 per QALY, respectively. Sensitivity analyses confirmed the robustness of the results. In summary, portable spirometer screening is likely the optimal option for COPD screening among chronic bronchitis patients China.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Cost-Benefit Analysis
Health Care Costs
Humans
Mass Screening
Primary Health Care
Pulmonary Disease, Chronic Obstructive* / diagnosis
Pulmonary Disease, Chronic Obstructive* / therapy